In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer,the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study,led by researchers from the Perelman School of Medicine [...]
| |||||
        
Bertalan Mesko,MD,PhD    Alzheimer's Disease Education & Referral Center  Colorectal Cancer Screen  CDC.gov  
 | Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis,a late stage European dermatology company with a focus on chronic pruritus (itch),has announced headline results of its Phase 2b trial with its lead product,CT327,in psoriasis patients. CT327 is a novel,topical,TrkA kinase inhibitor developed using Creabilis’[...] Nature Reviews Drug Discovery 12,335 (2013). doi:10.1038/nrd4017 Author:Charlotte Harrison Celgene’s oral phosphodiesterase 4 (PDE4) inhibitor apremilast has recently been shown to reduce disease severity in a Phase III trial of patients with psoriasis. Apremilast,together with other new investigational oral therapies such as Janus kinase (JAK) inhibitors could provide patients —especially [...] GDC-0032,a potent,next-generation PI3 kinase inhibitor,demonstrated early signs of efficacy for patients with cancers driven by mutations in the PI3 kinase alpha gene,according to first in-human results presented at the AACR Annual Meeting 2013. Mass General News Releases Objectives This study sought to compare the action of prasugrel and ticagrelor in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI). Background It has been documented that prasugrel and ticagrelor are able to provide effective platelet inhibition 2 h after a loading dose (LD). However,the pharmacodynamic measurements after prasugrel [...] Many recent studies have suggested that obesity is associated with chronic inflammation in fat tissues. Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered that an imbalance between an enzyme called neutrophil elastase and its inhibitor causes inflammation,obesity,insulin resistance,and fatty liver disease…Obesity / Weight Loss / Fitness News From Medical News [...] A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings suggest a strategy to improve the effectiveness of currently available targeted therapies. Mass General News Releases Abstract:Background:The treatment of immunoglobulin A (IgA) nephropathy with normal renal function and minimal proteinuria is unknown. Methods:We randomly assigned 60 patients with IgA nephropathy,proteinuria [...] Nature Reviews Rheumatology 9,2 (2013). doi:10.1038/nrrheum.2012.213 A phase II study examining the effects of GPLG0259,an inhibitor of MAP kinase-activated protein kinase 5 (MK5),in rheumatoid arthritis (RA) has been stopped. The MAP kinase cascade regulates cytokine production and is an attractive target for pharmacological intervention. 30 patients with methotrexate-refractory RA [...] Tocilizumab,a monoclonal antibody that blocks interleukin-6 receptors,was found effective against severe,persistent systemic juvenile idiopathic arthritis that had been unresponsive to all… Rheumatology News |
  --------------------------------------
University of Washington - Seattle,WA --------------------------------------  --------------------------------------  University of Washington - Harborview Medical CenterSeattle,WA   Office on Women's Health U.S. Department of Health and Human Services      "Watch your weight & your waist!"     CDC:Public Health
  
 U.S. Department of Health & Human ServicesNational Health Information Center
  | |||
| Copyright © 2013 Knowledge of Medicine - All Rights Reserved | Mission Statement | About Us | Contact Us | Hosted &Designed Whelan Technologies | Submit an Article | | |||||
